+

WO2005011701A1 - Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires - Google Patents

Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires Download PDF

Info

Publication number
WO2005011701A1
WO2005011701A1 PCT/EP2004/008185 EP2004008185W WO2005011701A1 WO 2005011701 A1 WO2005011701 A1 WO 2005011701A1 EP 2004008185 W EP2004008185 W EP 2004008185W WO 2005011701 A1 WO2005011701 A1 WO 2005011701A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
quinazoline
methoxy
fluorophenyl
chloro
Prior art date
Application number
PCT/EP2004/008185
Other languages
German (de)
English (en)
Inventor
Birgit Jung
Hubert Pueschner
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to EP04763394A priority Critical patent/EP1651228A1/fr
Priority to JP2006521478A priority patent/JP2007500156A/ja
Priority to CA002533752A priority patent/CA2533752A1/fr
Publication of WO2005011701A1 publication Critical patent/WO2005011701A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of quinazolines selected from the group consisting of
  • a medicament for the prevention and treatment of Respiratory or lung disorders associated with increased or altered mucus production, such as inflammatory respiratory disorders such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis , ⁇ 1-antitrypsin deficiency, for cough, emphysema, pulmonary fibrosis or hyperreactive airways.
  • inflammatory respiratory disorders such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis , ⁇ 1-antitrypsin deficiency, for cough, emphysema, pulmonary fibrosis or hyperreactive airways.
  • COPD chronic o
  • the compounds are also suitable for the treatment of inflammatory diseases of the gastrointestinal tract or of the bile ducts or gall bladder, which are associated with a disturbed activity of the tyrosine kinases, such as e.g. acute or chronic inflammatory changes such as cholecystitis, Crohn's disease, uitis ulcer, ulcers or polyposis in the gastrointestinal tract or how they occur in diseases of the gastrointestinal tract that are associated with increased secretion like M. Menetrier, secreting adenomas or protein loss syndromes,
  • inflammatory diseases of the joints such as rheumatoid arthritis, inflammatory diseases of the skin, eyes, inflammatory pseudopolyps, colitis cystica profunda or Pneumatosis cystoides intestinales.
  • COPD chronic bronchitis
  • COPD chronic sinusitis
  • asthma chronic bronchitis
  • Crohn's disease chronic sinusitis
  • colitis uicerosa or polyposis of the intestine.
  • COPD chronic bronchitis
  • Another object of the present invention is a method for the treatment of
  • Respiratory and lung disorders associated with increased or altered mucus production such as inflammatory Respiratory disorders such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, 1-antitrypsin deficiency, or for cough, pulmonary emphysema, pulmonary fibrosis and hyperreactive respiratory tract,
  • inflammatory Respiratory disorders such as acute bronchitis, chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, 1-antitrypsin deficiency, or for cough, pulmonary emphysema, pulmonary fibrosis and hyperreactive respiratory tract,
  • COPD chronic obstructive bronchitis
  • inflammatory diseases of the gastrointestinal tract and the bile ducts and gallbladder which are associated with a disturbed activity of the tyrosine kinases, such as e.g. acute or chronically inflammatory changes can be found, such as cholecystitis, Crohn's disease, uicerosa colitis and ulcers, and polyposis in the gastrointestinal tract or how they occur in diseases of the gastrointestinal tract that are associated with increased secretion like M. Menetrier, secreting adenomas and protein loss syndromes,
  • inflammatory diseases of the joints such as rheumatoid arthritis, of inflammatory diseases of the skin, of the eyes, of inflammatory pseudopolyps and of colitis cystica profunda and of pneumatosis cystoides intestinales,
  • the compounds mentioned are used in doses of 0.001-10 mg / kg of body weight, for example 0.5-0.7 mg / kg, preferably at 0.01-1.5 mg / kg, the administration advantageously being carried out 1 to 3 times a day.
  • the active substances can be administered orally, buccally, parenterally, by inhalation-atomization, rectally or topically.
  • Parenteral administration can include subcutaneous, intravenous, and intramuscular injections and infusion techniques.
  • Customary dosage forms can be used for administration, for example those mentioned in those cited above for the active substances Dosage forms.
  • the active ingredients optionally in combination with other active substances, together with one or more inert customary carriers and / or diluents, for example with corn starch, lactose, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / Ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethyl cellulose or fat-containing substances such as hard fat or their suitable mixtures, in usual galenical preparations such as tablets, dragees, capsules, powders, suspensions or suppositories.
  • the active ingredients can be administered orally in a wide variety of different dosage forms, for example together with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, cookies, hard candies, powders, atomizers, aqueous suspensions, elixirs, syrups and the like be formulated.
  • Such carriers include, for example, solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents.
  • such oral formulations can be sweetened and / or flavored in a suitable manner with the aid of various agents usually used for this purpose.
  • the active ingredients are present in such oral dosage forms with concentration levels, the range of which, based on the total composition, ranges from about 0.5% by weight to about 90% by weight, in amounts sufficient to give the desired dosage units.
  • concentration levels the range of which, based on the total composition, ranges from about 0.5% by weight to about 90% by weight, in amounts sufficient to give the desired dosage units.
  • suitable dosage forms for the active ingredients include controlled release formulations and devices that are well known to those skilled in the art.
  • solutions of the active ingredients in sesame or peanut oil or in aqueous propylene glycol can be used, as well as sterile aqueous solutions of the corresponding pharmaceutically acceptable salts.
  • aqueous solutions should, if necessary, be suitably buffered and the liquid diluent made isotonic with sufficient salt or glucose.
  • these certain aqueous solutions are particularly suitable for the purpose of intravenous, intramuscular and subcutaneous injections.
  • the sterile aqueous media used are easy to obtain using standard techniques which are well known to those skilled in the art.
  • the dosage form of the particular compound or compounds may include, for example, solutions, lotions, ointments, creams, gels, suppositories, permanent rate release formulations and devices therefor.
  • dosage forms include the particular compound or compounds and may include ethanol, water, penetrants and inert carriers such as gel generators, mineral oil, emulsifiers, benzyl alcohol and the like.
  • inhalable aerosols containing propellant gas which can be used in the context of the use according to the invention can contain the active ingredient or combination of active ingredients dissolved in the propellant gas or in dispersed form.
  • propellant gases which can be used to produce the inhalation aerosols are known from the prior art.
  • Suitable propellants are selected from the group consisting of hydrocarbons such as n-propane, n-butane or isobutane and halogenated hydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • hydrocarbons such as n-propane, n-butane or isobutane
  • halogenated hydrocarbons such as preferably fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the above-mentioned propellant gases can be used alone or in mixtures thereof.
  • Particularly preferred propellants are fluorinated alkane derivatives selected from TG134a (1, 1, 1, 2-tetrafluoroethane), TG227 (1, 1, 1, 2,3,3,3-heptafluoropropane) and mixtures thereof.
  • the inhalable aerosols containing propellant gas which can be used in the context of the use according to the invention can furthermore contain further constituents such as cosolvents, stabilizers, surface-active agents (surfactants), antioxidants, lubricants and agents for adjusting the pH. All of these components are known in the art.
  • aqueous or alcoholic, preferably ethanolic solutions are suitable as solvents.
  • the solvent can only be water or it is a mixture of water and ethanol.
  • the relative proportion of ethanol to water is not limited, but the maximum limit is preferably up to 70 volume percent, in particular up to 60 volume percent and particularly preferably up to 30 volume percent.
  • the remaining volume percentages are filled up with water.
  • the solutions or suspensions containing the active ingredient or combination of active ingredients are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. Acids selected from inorganic or organic acids can be used to adjust this pH.
  • Examples of particularly suitable inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and / or phosphoric acid.
  • Examples of particularly suitable organic acids are: Ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid, sulfuric acid.
  • Ascorbic acid, fumaric acid and citric acid are preferred among the organic acids.
  • mixtures of the above acids may be used, in particular in the case of acids, in addition to their acidifying other properties, such as flavorings, antioxidants or complexing agents, "such as citric acid or ascorbic acid.
  • hydrochloric acid to adjust the pH Value used.
  • the compounds of the general formula (I) and their salts have valuable properties, in particular an anti-inflammatory effect.
  • A 4 - [(R) - (1-phenyl-ethyl) amino] -6 - ⁇ [4 - ((R) -6-methyl-2-oxo-morpholin-4-yl) -1-oxo-2 buten-1-yl] amino ⁇ -7-methoxy-quinazoline,
  • Test 1 Inhibition of smoke-induced accumulation of granulocytes in the lung tissue
  • Indications of lunches Inhibition of the cigarette smoke-induced influx of neutrophils into the lung tissue by the EGF receptor kinase inhibitor 4 - [(R) - (1-phenyl-ethyl) amino] -6 - ⁇ [4 - ((R) -6 -methyl-2-oxo-morpholin-4-yl) -1 - oxo-2-buten-1-yl] amino ⁇ -7-methoxy-quinazoline (compound A).
  • mice Male rats (strain: Sprague-Dawley) weighing 250-300 g were exposed to the smoke of 8 cigarettes a day for 5 days.
  • the animals in the compound A-treated group received intratracheal administration of 0.03 or 0.1 mg / kg of the compound A in a volume of 0.05 ml daily under anesthesia with isoflurane 30 minutes before the start of smoking exposure.
  • the animals On the last day of the experiment, the animals were sacrificed 4 hours after the last smoke exposure and the lung tissue was removed.
  • a sample of 70-200 mg was taken from each lung and placed in a reaction vessel prepared with 1 ml of 0.5% hexadecyltrimethylammonium bromide. The samples were homogenized with an Ultraturrax for 15 seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de quinazolines sélectionnées, de tautomères, de stéréoisomères et de sels de celles-ci, notamment de sels de celles-ci physiologiquement compatibles, avec des acides ou des bases organiques ou inorganiques, pour produire un médicament permettant de prévenir ou de traiter des maladies des voies respiratoires ou des poumons, ainsi que d'autres maladies inflammatoires.
PCT/EP2004/008185 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires WO2005011701A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04763394A EP1651228A1 (fr) 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires
JP2006521478A JP2007500156A (ja) 2003-07-28 2004-07-22 炎症性プロセスの治療におけるキナゾリンチロシンキナーゼ阻害剤の使用
CA002533752A CA2533752A1 (fr) 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10334226.5 2003-07-28
DE10334226A DE10334226A1 (de) 2003-07-28 2003-07-28 Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse

Publications (1)

Publication Number Publication Date
WO2005011701A1 true WO2005011701A1 (fr) 2005-02-10

Family

ID=34071934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/008185 WO2005011701A1 (fr) 2003-07-28 2004-07-22 Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires

Country Status (5)

Country Link
EP (1) EP1651228A1 (fr)
JP (1) JP2007500156A (fr)
CA (1) CA2533752A1 (fr)
DE (1) DE10334226A1 (fr)
WO (1) WO2005011701A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082129A1 (fr) * 2005-02-04 2006-08-10 Boehringer Ingelheim International Gmbh Utilisation d'inhibiteurs de tyrosine kinase pour traiter la rhino-sinusite chronique
JP2008531536A (ja) * 2005-02-26 2008-08-14 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2017141271A1 (fr) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique stable d'afatinib

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20020077330A1 (en) * 2000-08-26 2002-06-20 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
WO2002050043A1 (fr) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
US20020082271A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20020173509A1 (en) * 2000-12-20 2002-11-21 Frank Himmelsbach Quinazoline derivatives and phamaceutical compositions containing them
WO2003082290A1 (fr) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(n-phenylamino)-quinazolines / quinolines en tant qu'inhibiteurs de la tyrosine kinase
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10231711A1 (de) * 2002-07-13 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20020077330A1 (en) * 2000-08-26 2002-06-20 Frank Himmelsbach Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US20020082271A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
WO2002050043A1 (fr) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
US20020173509A1 (en) * 2000-12-20 2002-11-21 Frank Himmelsbach Quinazoline derivatives and phamaceutical compositions containing them
WO2003082290A1 (fr) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(n-phenylamino)-quinazolines / quinolines en tant qu'inhibiteurs de la tyrosine kinase
DE10214412A1 (de) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10231711A1 (de) * 2002-07-13 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARKER, A. J. ET AL: "Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 11(14), 1911-1914 CODEN: BMCLE8; ISSN: 0960-894X, 2001, XP008039295 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082129A1 (fr) * 2005-02-04 2006-08-10 Boehringer Ingelheim International Gmbh Utilisation d'inhibiteurs de tyrosine kinase pour traiter la rhino-sinusite chronique
JP2008531536A (ja) * 2005-02-26 2008-08-14 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
WO2017141271A1 (fr) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique stable d'afatinib

Also Published As

Publication number Publication date
DE10334226A1 (de) 2005-02-17
CA2533752A1 (fr) 2005-02-10
JP2007500156A (ja) 2007-01-11
EP1651228A1 (fr) 2006-05-03

Similar Documents

Publication Publication Date Title
WO2003066060A2 (fr) Utilisation d'inhibiteurs de tyrosine kinase pour traiter des processus inflammatoires
US20070004720A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
WO2003094921A2 (fr) Utilisation d'inhibiteurs de la transduction de signal induite par le recepteur egf dans le traitement de l'hyperplasie/hypertrophie benigne de la prostate
DE60121012T2 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
DE69526790T2 (de) Verbindungen zur hemmung von phosphodiesrerase iv
EP1853596B1 (fr) Nouveaux betamimetiques a effet prolonge pour traiter des affections des voies respiratoires
WO2007042467A1 (fr) Nouvelles combinaisons medicamenteuses destinees au traitement de maladies respiratoires
EP1765355B1 (fr) Benzoxazines destinees au traitement de maladies des voies respiratoires
EP1682147B1 (fr) Utilisation d'inhibiteurs de tyrosine-kinase pour traiter des processus inflammatoires
WO2006082129A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase pour traiter la rhino-sinusite chronique
WO2005011701A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase a base de quinazoline pour traiter des processus inflammatoires
US20050059661A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
EP1478398B1 (fr) Nouvelles compositions de m dicaments base d'anticholinergiques et d'inhibiteurs de kinase egfr
EP1658860A1 (fr) Compositions pharmaceutiques renfermant des anticholinergiques et des inhibiteurs de l'EGFR kinase
EP1379225B1 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de l'endotheline
DE102005005505A1 (de) Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung der chronischen Rhinosinusitis
US20140364445A1 (en) Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
DE102004001607A1 (de) Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
EP3600275A1 (fr) Composition de sirop pharmaceutique stabilisée comprenant du sulfate de terbutaline et du chlorhydrate d'ambroxol
DE69621706T2 (de) Verwendung von Piperazinverbindungen als narkotische Antagonisten
CN116621893A (zh) 一种牛蒡子苷衍生物及其制备方法和应用
US9238019B2 (en) Antitussive and bronchodilator uses for enaminone ester
CN116270454A (zh) 盐酸丙卡特罗口服溶液及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763394

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2533752

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006521478

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004763394

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004763394

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载